← Back to Search

CAR T-cell Therapy

JNJ-90009530 for B-Cell Lymphoma

Phase 1

Recruiting

Research Sponsored by Cellular Biomedicine Group, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 24 months

Awards & highlights

Study Summary

This trial studies a drug to treat patients with non-Hodgkin Lymphoma who have not responded to other treatments. It will test if the drug is safe and effective.

Who is the study for?

This trial is for adults over 18 with B-Cell Non-Hodgkin Lymphoma that's come back or didn't respond after at least two treatments, and relapsed within a year of the last treatment. Participants must have a certain level of physical fitness (ECOG status 0 or 1) and their tumors must test positive for CD20.Check my eligibility

What is being tested?

The study tests JNJ-90009530 to find a safe dose that patients can tolerate well, see if it helps reduce cancer symptoms, and how long any benefits last. It's conducted across multiple centers where participants receive this experimental drug.See study design

What are the potential side effects?

While specific side effects are not listed here, typical ones from similar trials may include fatigue, nausea, allergic reactions to the drug infusion, lowered blood cell counts increasing infection risk, liver or kidney function changes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Calculate the Occurence of Adverse Events

Determine Recommended Phase 2 dose (RP2D)

Secondary outcome measures

Determine the Overall Response (OR)

Determine the duration of response (DOR)

Determine the time to response (TTR)

+1 more

Other outcome measures

Evaluate overall survival

Evaluate progression-free survival

Evaluate the concentration of anti-drug antibodies (ADA)

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: JNJ-90009530Experimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Cellular Biomedicine Group, Inc.Lead Sponsor

2 Previous Clinical Trials

124 Total Patients Enrolled

Mayo ClinicOTHER

3,216 Previous Clinical Trials

3,767,396 Total Patients Enrolled

Janssen Research & Development, LLCLead Sponsor

976 Previous Clinical Trials

6,384,600 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the intended outcome of this medical study?

"This trial has two main objectives: to establish the Recommended Phase 2 Dose (RP2D) of the medication over a period up to 24 months, and secondly ascertain secondary outcomes such as Duration of Response (DOR), Chimeric Antigen Receptor Copy Number evolution through Quantitative Polymerase Chain Reaction (qPCR) measurements, and Time To Response (TTR)."

Answered by AI

Are there any available opportunities to join this research experiment?

"According to information shared on clinicaltrials.gov, this trial is currently searching for participants. It was first publicized on November 6th 2023 and has recently had edits applied in the form of a revision made on 15th November 2023."

Answered by AI

How many individuals have opted to participate in this research endeavor?

"Confirmed. According to clinicaltrials.gov, this study was first posted on November 6th 2023 and is presently recruiting participants for the trial. The project requires 92 individuals from a single site to be enrolled."

Answered by AI

Has JNJ-90009530 been given the go-ahead by the FDA?

"Due to the limited data surrounding JNJ-90009530, our team placed its safety rating at 1. This is because it is currently in a Phase 1 trial where efficacy and security have yet to be fully evaluated."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

2023. "A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05784441.